Compare Under Armour Inc Class A (UAA) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Under Armour Inc Class A vs GeneDx Holdings Corp — how do they compare? Under Armour Inc Class A trades at $5.07 (market cap $2.15B), while GeneDx Holdings Corp trades at $86.53 (market cap $2.56B). The key difference: GeneDx Holdings Corp is the larger of the two by market cap, and GeneDx Holdings Corp is trading nearer its 52-week high, Under Armour Inc Class A nearer its low. Which is the better fit depends on your goals.
| UAA | WGS | |
|---|---|---|
Market Cap | $2.15B | $2.56B |
Sector | Consumer Cyclical | Technology |
52-Week High | $8.14 | $167.51 |
52-Week Low | $4.17 | $34.51 |
Enterprise Value | $3.13B | $2.60B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Under Armour (UAA) trades at $5.06, down 3.62% on the day, reflecting persistent investor concerns. The stock is technically bearish, with moving averages signaling a downtrend. Fundamentally, the company reported a net loss of $201.27 million in 2025, with revenue declining to $5.16 billion. Recent news highlights a reduced revenue outlook for fiscal 2027, though cost discipline aims to preserve profitability.
The outlook remains challenging due to weak North American demand and falling revenue projections. Analyst consensus is a 'Hold' with a $6.67 price target, indicating cautious optimism for margin recovery. Key risks include sustained sales weakness and high debt levels. The stock offers potential upside if margin improvements materialize, but near-term headwinds dominate.
WGS trades at $85.87, down 0.14% today, with a bullish technical signal from moving averages and support at $84. The company reported Q2 2026 revenue of $114.4M, beating estimates, and returned to adjusted profitability early. However, net income remains negative at -$106M for 2026, with high valuation multiples like EV/EBITDA of 161.17. Recent news highlights partnerships and product launches, such as the NPC GenomeComplete initiative with Beren Therapeutics.
Outlook is mixed: strong analyst buy consensus (90.9%) and institutional interest support upside, but profitability challenges and a class action lawsuit pose risks. Revenue growth and operational improvements are key catalysts, yet high debt-to-asset ratios and negative margins require monitoring for sustained recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Under Armour Inc Class A
Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America and other territories. Consumers of its apparel include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through direct-to-consumer, including e-commerce and more than 400 combined factory house and brand house stores, and wholesale channels. Under Armour also operates a digital fitness app called MapMyFitness. The Baltimore-based company was founded in 1996.
Read more on UAA →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
